Novel Effect of p-Coumaric Acid on Hepatic Lipolysis: Inhibition of Hepatic Lipid-Droplets
Molecules · 2023
DOI: 10.3390/molecules28124641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Zhiyi Yuan und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chongqing Medical University, Chongqing 400016, China. Hauptthemen laut MEDLINE: Lipolysis, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National S&T Major Special Project for New Drug R&D Program of China, the National Natural Science Foundation of China, Youth Fund of National Natural Science Foundation, China.
Abstract (Originalsprache)
p-coumaric acid (p-CA), a common plant phenolic acid with multiple bioactivities, has a lipid-lowering effect. As a dietary polyphenol, its low toxicity, with the advantages of prophylactic and long-term administration, makes it a potential drug for prophylaxis and the treatment of nonalcoholic fatty liver disease (NAFLD). However, the mechanism by which it regulates lipid metabolism is still unclear. In this study, we studied the effect of p-CA on the down-regulation of accumulated lipids in vivo and in vitro. p-CA increased a number of lipase expressions, including hormone-sensitive lipase (HSL), monoacylglycerol lipase (MGL) and hepatic triglyceride lipase (HTGL), as well as the expression of genes related to fatty acid oxidation, including long-chain fatty acyl-CoA synthetase 1 (ACSL1), carnitine palmitoyltransferase-1 (CPT1), by activating peroxisome proliferator-activated receptor α, and γ (PPARα and γ). Furthermore, p-CA promoted adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK) phosphorylation and enhanced the expression of the mammalian suppressor of Sec4 (MSS4), a critical protein that can inhibit lipid droplet growth. Thus, p-CA can decrease lipid accumulation and inhibit lipid droplet fusion, which are correlated with the enhancement of liver lipases and genes related to fatty acid oxidation as an activator of PPARs. Therefore, p-CA is capable of regulating lipid metabolism and is a potential therapeutic drug or health care product for hyperlipidemia and fatty liver.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
- School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.
- Institute of Medicinal Plant and Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100094, China.
Förderung
- the National S&T Major Special Project for New Drug R&D Program of China
- the National Natural Science Foundation of China
- Youth Fund of National Natural Science Foundation, China
- Program for Youth Innovation in Future Medicine, Chongqing Medical University
- National S&T Major Special Project for New Drug R&D Program of China
- National Natural Science Foundation of China
- Chongqing Special Foundation for Postdoctoral Research Proposal, China
- Program for Youth Innovation in Future Medicine, Chongqing Medical University, China
Zitieren
APA
Yuan, Z., Lu, X., Lei, F., Sun, H., Jiang, J., Xing, D., & Du, L. (2023). Novel Effect of p-Coumaric Acid on Hepatic Lipolysis: Inhibition of Hepatic Lipid-Droplets. Molecules. https://doi.org/10.3390/molecules28124641
Vancouver
Yuan Z, Lu X, Lei F, Sun H, Jiang J, Xing D, et al. Novel Effect of p-Coumaric Acid on Hepatic Lipolysis: Inhibition of Hepatic Lipid-Droplets. Molecules. 2023. doi:10.3390/molecules28124641
BibTeX
@article{Yuan2023,
author = {Yuan, Zhiyi and Lu, Xi and Lei, Fan and Sun, Hong and Jiang, Jingfei and Xing, Dongming and Du, Lijun},
title = {Novel Effect of p-Coumaric Acid on Hepatic Lipolysis: Inhibition of Hepatic Lipid-Droplets},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28124641}
}
EUVIMED